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A B S T R A C T 
Congenital Short QT Syndrome (SQTS) is a rare but dangerous condition involving abbreviated ventricular 
repolarization and an increased risk of atrial and ventricular arrhythmias. Taking the example of the first 
identified SQTS mutation, N588K-hERG, we consider briefly the basic science approaches used to obtain 
an understanding of the mechanism(s) of arrhythmogenesis in this form of the syndrome. A combination of 
recombinant channel electrophysiology and in silico simulations has provided insights into causality 
between the identified mutation, accelerated repolarization and increased susceptibility to re-entry in 
N588K-hERG-linked SQTS. Subsequent studies employing a transgenic rabbit model or human induced 
pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) have further demonstrated mechanisms 
predisposing to re-entry, spiral wave activity and arrhythmia in intact tissue. The complementarity between 
the findings made using these different approaches gives confidence that, collectively, they have identified 
major arrhythmia mechanisms and their potential mitigation by Class I antiarrhythmic drugs in this form of 
SQTS. 
 
                                                              © 2020 Jules C Hancox. by Science Repository. All rights reserved. 
 
Introduction 
Congenital short QT syndrome (SQTS) is a rare but dangerous condition 
characterized by abbreviated ventricular repolarization; it is associated 
with an increased risk of atrial and ventricular arrhythmias and of sudden 
death [1, 2]. Whilst a number of different genes have been associated 
with the SQTS, the most commonly found mutations in SQTS patients 
to date are to hERG (human-Ether-à-go-go Related Gene; alternative 
nomenclature KCNH2) encoded potassium channels [2-4]. hERG 
channels mediate the rapid delayed rectifier potassium (K+) current (IKr), 
which works in conjunction with other ion channels to repolarize the 
ventricular action potential [5-7]. Mutations to hERG have long been 
established to be responsible for the LQT2 form of congenital long QT 
syndrome (LQTS), whilst a unique propensity of hERG channels to 
pharmacological blockade underpins the channel’s involvement in the 
drug-induced form of LQTS [8, 9]. 
 
The first SQTS variant (SQT1) to be identified was found in two families 
in which different missense mutations led to a common amino acid 
substitution (Asparagine → Lysine; N588K) in the external S5-Pore 
region of the channel [10]. This region is important to rapid voltage-
dependent inactivation of the hERG channel and experiments on 
heterologously expressed recombinant hERG channels demonstrated 
conclusively that the N588K mutation produces a marked positive shift 
in voltage-dependent inactivation of hERG current (IhERG) that results in 
a marked increase in outward potassium current; this in turn accelerates 
repolarization and abbreviates refractoriness [10-13]. The attenuated 
voltage-dependent inactivation in N588K hERG channels makes them 
less amenable to pharmacological blockade by Class III selective IKr 
inhibiting antiarrhythmic drugs (a drug class that includes sotalol and 
dofetilide), though the channels retain some sensitivity to the Class Ia 
antiarrhythmics quinidine and disopyramide [10, 14-16]. Consistent with 
this, SQT1 patients with the N588K mutation are unresponsive to sotalol 
but have been reported to respond favourably to quinidine and 
disopyramide [3, 10, 15, 17, 18]. 
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The understanding of underlying arrhythmia mechanisms in the SQTS 
has relied for a long time on pharmacological models of the SQTS or in 
silico studies using cell and tissue electrophysiological models. The 
N588K SQT1 mutation is the best studied SQTS mutation in this regard 
[2, 19]. Unfortunately, arrhythmia mechanisms in hERG-linked 
channelopathies cannot reliably be studied using genetically modified 
mice, as mice have evolved with high heart rates, abbreviated ventricular 
action potentials (APs) and ventricular repolarisation mechanisms that 
differ from those in humans, without a reliance on IKr [20]. The use of 
single cell ventricular AP models has demonstrated a causal link between 
the N588K mutation and AP shortening, whilst tissue models 
incorporating transmural heterogeneity in IKr were able to reconstitute 
QT interval shortening and increases in T wave amplitude similar to 
those seen in patients [13, 21].  
 
Maximal transmural heterogeneity was found to be augmented at some 
locations in ventricular tissue models and refractoriness was abbreviated 
as a consequence of AP shortening [13]. In 2D and 3D models, this led 
to a reduced substrate size required to support re-entry and increased 
spiral/scroll wave lifespan [13]. The subsequent incorporation of 
electromechanical coupling led to reductions in Ca2+ transients and 
contractile force under conditions simulating the N588K mutation and 
altered timing of maximal mechanical deformation in 3D tissue models 
[22]. Consistent with this, a modest reduction in ventricular myocyte 
shortening has been observed to accompany AP shortening induced by a 
pharmacological hERG activator [2]. Such findings are qualitatively 
consistent with modest systolic changes observed using Doppler 
imaging and speckle-tracking echocardiography in SQTS patients [23]. 
A simulation approach has also been used to explore the atrial 
arrhythmia substrate and its susceptibility to modification by Class I 
antiarrhythmic drugs in N588K-linked SQTS [24]. 
 
Recently, an animal model of N588K-linked SQTS has been published 
using a species with repolarization mechanisms more similar to those in 
humans: transgenic rabbits were generated that expressed N588K hERG 
channels [25]. This model showed abbreviation of the QT interval, AP 
duration, atrial and ventricular refractory periods and a decrease in slope 
of the QT/RR relationship [25]. These changes are consistent with the 
clinical phenotype in the syndrome, though tall T waves seen in humans 
were not evident in the rabbit ECGs [25]. In contrast with in silico and 
patient data systolic function was not altered in SQT1 rabbits, though 
diastolic relaxation was enhanced [22, 23, 25]. Inducibility of ventricular 
tachycardia (VT)/ ventricular fibrillation (VF) was increased in the 
SQT1 model, whilst quinidine prolonged AP and QT interval duration 
[25]. One intriguing finding was the presence of some ionic current 
remodelling in myocytes from SQT1 rabbits: the inwardly rectifying 
potassium current, IK1 was decreased (which would partially oppose the 
gain-of-function effect of increased IKr in SQT1), whilst the slow delayed 
rectifier K+ current (IKs) showed a small increase (which could be 
synergistic with the increased IKr in SQT1) [25]. Such observations could 
only be made using an experimental and not in silico approach, though 
the relevance of this finding to SQT1 in patients is not yet clear. 
 
Another promising experimental approach to the study of arrhythmia 
mechanisms in the SQTS has been the generation of mutation-specific 
human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. 
El-Battrawy et al. have generated hiPSCs from SQT1 (N588K) patient 
and control fibroblasts and derived cardiomyocytes (hiPSC-CMs) from 
these [26]. Consistent with the simulation and transgenic rabbit findings 
discussed above, increased IKr density and shortened AP duration were 
seen in N588K-hiPSC-CMs compared to control hiPSC-CMs. Abnormal 
Ca2+ transients and arrhythmic activities were also evident and quinidine 
prolonged AP duration [26]. Carbachol was found to exacerbate 
arrhythmic events in N588K-hiPSC-CMs and quinidine mitigated this 
effect. There was no change in mRNA for KCNJ2 or KCNQ1, which 
respectively encode IK1 and IKs channel subunits, but mRNA for hERG 
itself and CACNA1C (L-type Ca channel) and KCND3+KCHIP2 
(transient outward potassium channel) were all increased in N588K-
hiPSC-CMs [26]. A limitation in the use of hiPSC-CM is their well-
known immature phenotype, evidenced here by the fact that cells were 
spontaneously active, which is not the case for mature ventricular 
myocytes [26].  
 
Nevertheless, the overall phenotype seen is broadly consistent with those 
from other approaches. Subsequent use of N588K-hiPSC-CMs has 
probed the potential for additional pharmacological approaches to this 
form of SQT1, finding potential utility for ivabradine, ajmaline and 
mexiletine, at least in vitro [27]. Of course, the hiPSC-CM approach has 
wider applicability than solely to the N588K hERG mutation and it has 
also been used to confirm a causal relationship between the T618I hERG 
gain-of-function SQT1 mutation and abbreviation of repolarization [28, 
29]. 
 
A further elaboration of the hiPSC-CM approach to studying SQT1 has 
come from the combination of experiments on individual hiPSC-CMs 
with work on 2 dimensional hiPSC-CM sheets [30]. 
Electrophysiological characteristics have been compared at the cell and 
multicellular levels in an hiPSC-CM line from a patient with N588K-
hERG-linked SQT1 and isogenic control and healthy hiPSC-CM 
preparations. As may be anticipated, increased IKr together with 
abbreviated repolarization and refractory periods were observed in 
hiPSC-CM expressing the N588K mutation [30]. Optical mapping of 
SQT1 hiPSC-CM sheets revealed abbreviated action potential duration 
(APD) and excitation wavelength, impaired APD rate-adaptation and 
increased inducibility of sustained spiral waves [30]. Spiral waves had 
accelerated rotation and increased stability, frequency, stationarity and 
wave front curvature near their cores. Quinidine and disopyramide, but 
not sotalol, prolonged APD and suppressed arrhythmia [30]. 
 
There is striking concordance between the results of this study and 
earlier published work using in silico electrophysiological simulations 
of N588K-hERG-linked SQT1 [13, 30, 31]. In simulations, modification 
of IKr based on N588K hERG channel data led to abbreviated APD and 
effective refractory period (ERP), flattening of APD and ERP restitution 
(i.e. impaired APD rate-adaptation) [13]. In 2D and 3D tissue 
simulations, SQT1 reduced the excitation wavelength but increased 
tissue susceptibility to re-entry with higher dominant frequencies [13]. 
When known actions of quinidine and disopyramide were incorporated 
into SQT1 simulations, both drugs prolonged QT interval (due to IKr 
block), ERP (due to a combination of IKr and Na current (INa) block), re-
entry wavelength and exhibited antifibrillatory effects [31].  
 
The consideration of what experimental and in silico approaches have 
collectively revealed about N588K-hERG-linked SQT1 is instructive in 
several respects.  First, the mechanistic insights into arrhythmogenesis 
in SQT1 from transgenic rabbit and hiPSC-CM preparations are largely 
in agreement with those obtained from earlier computer simulation 
work.  This engenders confidence in the conclusions reached from the 
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incorporation of data from experiments on recombinant channels into 
biophysically accurate computer simulations using human cardiac 
electrophysiology models. Perhaps the only significant potential deficit 
in this approach is that on its own it cannot detect potential 
accompanying electrical remodelling that may be observed using hiPSC-
CMs or transgenic animal approaches [25, 26]. That said, it is notable 
that the remodelling seen in N588K hERG transgenic rabbits differed 
from that in hiPSC CMs expressing the same SQT1 mutation and the 
arrhythmia mechanisms suggested from hiPSC-CM sheets are similar to 
those seen in computer models of the same mutation that did not 
incorporate remodelling of other channels [13, 25, 26, 30].  
 
Of the different approaches used, recombinant channel 
electrophysiology together with computational modelling is likely to be 
the least expensive, whilst generation and study of mutation-specific 
transgenic rabbits likely to be the most expensive, although of potentially 
high value for considering responses at the whole heart level. The small 
size of native IKr in both hiPSC-CMs and adult cardiac myocytes, 
together with the presence of overlapping conductances, is likely to 
make detailed interrogation of changes to channel kinetics due to gain of 
function mutations much more difficult than is the case for experiments 
using recombinant channels expressed in appropriate mammalian cell 
lines. This limitation to native cardiac myocytes use may be exacerbated 
for mutations that impair IKr inactivation, as this can impair selective IKr 
blocker action and thus measurement of IKr as a drug-sensitive current 
could, at least in principle, underestimate native magnitude under gain-
of-function mutant conditions. 
 
Conclusion 
 
It is reasonable to conclude that an initial approach to investigating 
pathogenicity of gain-of-function hERG mutations, as considered here 
for the N588K-hERG-linked SQT1 mutation, is to quantify effects on 
recombinant channel function, then to use those data to interrogate 
causality in human cardiac AP models. The findings of such studies can 
then subsequently be further validated/interrogated using mutation-
specific hiPSC-CM lines, potentially at both the cellular and 
multicellular levels. The feasibility of the future routine use of 
genetically modified rabbits (or indeed another appropriate model 
species) for this kind of work is likely to depend on technological 
advances to increase cost- and time-effectiveness of the approach. 
Ultimately, the ability to combine multiple complementary approaches 
is likely to highlight common mechanistic findings that shed light onto 
arrhythmogenic mechanisms and approaches to their possible treatment 
in such syndromes. 
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